Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
18 Years and older, Male and Female
S2013 (primary)
S2013
S2013
NCI-2021-01262
Summary
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body’s immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Objectives
PRIMARY OBJECTIVE:
I. To both develop and independently validate risk prediction models for development of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher non-hematological immune-related adverse events (irAEs) in the first year of treatment for two cohorts of patients with solid tumors: (1) immune checkpoint inhibitor (ICI) therapy alone and (2) ICI therapy in combination with chemotherapy (chemo-ICI).
SECONDARY OBJECTIVES:
I. To prospectively assess the incidence of any grade of non-hematological irAEs and grade 4 hematological irAEs over 12 months. (In each treatment setting [ICI alone and chemo-ICI])
II. To observe the trajectory of patient-reported quality of life and health preferences over 12 months. (In each treatment setting [ICI alone and chemo-ICI])
III. To observe the trajectory of patient-reported adverse events over 12 months using serial assessment with select Patient-Reported Outcomes versions of the CTCAE (Patient-Reported Outcomes [PRO]-CTCAE) measures. (In each treatment setting [ICI alone and chemo-ICI])
IV. To measure the burden of chronic, grade 1 and 2 toxicities using methods such as toxicity over time (ToxT). (In each treatment setting [ICI alone and chemo-ICI])
V. To track patterns of treatment of irAEs and patterns of toxicity resolution. (In each treatment setting [ICI alone and chemo-ICI])
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To evaluate the cytokine toxicity (CYTOX) score, a composite measure derived from 11 different cytokine levels, both prior to treatment and after 1 cycle of treatment as a predictive signature for the development of irAEs.
II. To establish a repository of archival tissue and blood, serum, and stool specimens for potential predictive and/or prognostic markers of irAE risk.
ADDITIONAL OBJECTIVES:
I. To assess the feasibility of using electronic (e)PRO in a multi-center clinical trial setting.
II. To analyze correlations between weight-based prescription or fixed dose and incidence of adverse events and immune mediated adverse events.
III. To explore associations between incidences of grade 3 or higher irAEs over 12 months and self-reported dietary fiber intake assessed with dietary screener questionnaire at baseline and at 4 weeks (+/- 2 weeks). Self-reported dietary fiber will also be correlated with stool microbiome characteristics and the CYTOX score.
OUTLINE:
Patients undergo collection of a tissue sample at the start of their routine cancer treatment. Patients complete questionnaires at the start of cancer treatment, weeks 4, 12, 24, and 52. Patients have the option of providing blood and stool samples at several time points during the study.
Eligibility
- Participants must be planning to receive ICI-based therapy or chemo-ICI for a solid tumor malignancy. This therapy must be given according to National Comprehensive Cancer Network (NCCN) guidelines at Category 1 or 2A and not in the context of a clinical trial
- Participants who have received prior ICI-based therapy must have completed ICI-based therapy at least 180 days prior to registration
- Participants must not have discontinued any prior ICI-based therapy (if applicable) because of irAE
- Participants must not have received chemotherapy, biologic, or targeted-therapy within 14 days prior to registration. Hormonal therapy is allowed
- Participants must have recovered from side effects of prior therapy to the following standards per treating physician’s discretion: * =< Grade 1 for any non-hematologic side effects (excluding neuropathy and alopecia); lab-related parameters of liver and renal function will be considered at the discretion of the treating physician) * =< Grade 2 for neuropathy and/or alopecia * Grade 3 or less for any hematologic side effects
- Participants must be planning to begin standard of care ICI-based therapy or one of the chemo-ICI regimens within 7 calendar days after registration
- Participants in the ICI-alone cohort must not be planning to receive ICI-based therapy in combination with chemotherapy or any other non-ICI therapy for treatment of their cancer. Palliative radiation is allowed
- Participants in the chemo-ICI cohort must not be planning to receive any targeted or non-ICI biologic therapy for treatment of their cancer
- Participants may receive palliative radiation, growth factor support and osteoclast inhibitor therapy per treating physician’s discretion in both cohorts
- Participants must be at least 18 years of age
- Participants must complete their history and physical examination within 28 days prior to registration
- Participants must be able to complete Patient-Reported Outcome (PRO) instruments in English, Spanish, or French (as applicable) and must be planning to complete these PROs at all scheduled assessments * NOTE: The Dietary Screener Questionnaire (DSQ) is only applicable to participants enrolled after the release and implementation of revision #5 (Version Date 11/1/2023)
- Participants must be able to complete Patient-Reported Outcome (PRO) instruments in English, Spanish, or French and must be planning to complete PROs at all scheduled assessments
- Participants must complete the pre-registration (baseline) PRO forms within 14 days prior to registration
- Participants must be willing to participate in PRO data collection * Note: Prior to registration, participants must decide on their method (paper or electronic) of completing their follow-up questionnaires. Participants who elect electronic (ePRO) completion must have an iPhone, Android phone, or tablet with cellular or WiFi connectivity in order to download the Patient Cloud mobile applications onto the device (personal device or a site provisioned device for multi-users)
- Participants registered by sites located in the United States must be offered the opportunity to participate in the optional specimen banking. With participant consent, specimens must be collected and submitted
- Participants registered by sites located outside of the United States (US) must be offered the opportunity to participate in the optional plasma and buffy coat specimen banking collection. With participant consent, plasma and buffy coat specimens must be collected and submitted * NOTE: The optional whole blood and stool collection is limited to participants at US sites only. The optional stool collection is available only to participants enrolled after the release and implementation of Revision #3 (Version Date 3/30/2023)
- Note: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system. * Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
Treatment Sites in Georgia
1831 Fifth Avenue
Columbus, GA 31904
706-780-6201
NGMC-Gainesville
Wisteria Building Suite 420
200 South Enota
Gainesville, GA 30501
770-219-8822
www.nghs.com
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.